Image 1_Ticagrelor vs. clopidogrel in dual antiplatelet therapy after coronary artery bypass surgery: a meta-analysis.tif by Liyuan Wang (795570)

“…</p>Results<p>4 randomized controlled trials and 3 observational studies (n = 2,424) were eligible for final analysis. A + T was associated with a decreased risk of all-cause mortality (OR = 0.47, 95% CI 0.31–0.70, p < 0.001, p heterogeneity = 0.80, I² = 0%) and cardiovascular mortality (OR = 0.50, 95% CI 0.31–0.82, p = 0.006, p heterogeneity = 0.71, I² = 0%), compared with A + C group. …”

Time’s Up. Descriptive Epidemiology of Multi-Morbidity and Time Spent on Health Related Activity by Older Australians: A Time Use Survey by Tanisha Jowsey (396920)

“…A recall questionnaire was developed, piloted, and adjusted. …”

Table1_Safety and efficacy of NOAC vs. VKA in patients treated by PCI: a retrospective study of the FRANCE PCI registry.docx by Eric Durand (197728)

“…VKA-treated participants [3.1% vs. 5.2%, −2.1% (−3.6% to −0.6%), p = 0.005 as well as the rate of MACE [9.2% vs. 11.9%, −2.7% (−5.0% to −0.4%), p = 0.02]. One-year mortality was also significantly decreased in NOAC vs. …”

Pre- and Neonatal Exposure to Lipopolysaccharide or the Enteric Metabolite, Propionic Acid, Alters Development and Behavior in Adolescent Rats in a Sexually Dimorphic Manner by Kelly A. Foley (512965)

“…Pregnant Long-Evans rats were subcutaneously injected once a day with PPA (500 mg/kg) on gestation days G12–16, LPS (50 µg/kg) on G15–16, or vehicle control on G12–16 or G15–16. …”

Table 1_Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases.docx by Xianyu Dai (18939514)

“…Background<p>Urinary retention (UR) is a clinical condition where patients cannot fully empty their bladder. …”

Image 2_Ticagrelor vs. clopidogrel in dual antiplatelet therapy after coronary artery bypass surgery: a meta-analysis.tif by Liyuan Wang (795570)

“…</p>Results<p>4 randomized controlled trials and 3 observational studies (n = 2,424) were eligible for final analysis. A + T was associated with a decreased risk of all-cause mortality (OR = 0.47, 95% CI 0.31–0.70, p < 0.001, p heterogeneity = 0.80, I² = 0%) and cardiovascular mortality (OR = 0.50, 95% CI 0.31–0.82, p = 0.006, p heterogeneity = 0.71, I² = 0%), compared with A + C group. …”

Table2_Safety and efficacy of NOAC vs. VKA in patients treated by PCI: a retrospective study of the FRANCE PCI registry.docx by Eric Durand (197728)

“…VKA-treated participants [3.1% vs. 5.2%, −2.1% (−3.6% to −0.6%), p = 0.005 as well as the rate of MACE [9.2% vs. 11.9%, −2.7% (−5.0% to −0.4%), p = 0.02]. One-year mortality was also significantly decreased in NOAC vs. …”

Data_Sheet_1_Surviving in a new host: Eight years of monitoring translocated aroids, bromeliads, and orchids in the Andean forests in Colombia.docx by Ana María Benavides (14632568)

Data_Sheet_1_Dietary intake, physical activity and sedentary behavior and association with BMI during the transition to parenthood: a prospective dyadic study.docx by Vickà Versele (16010936)

Data_Sheet_1_Hypoglossal nerve stimulation in adolescents with down syndrome and obstructive sleep apnea: A systematic review and meta-analysis.docx by Pan Liu (527011)

“…A total of 106 patients were included. All the studies showed that patients receiving hypoglossal nerve stimulation experienced a significant decrease in apnea-hypopnea index (at least 50%). …”

DataSheet_1_Effects of sleep duration and changes in body mass index on diabetic kidney disease: a prospective cohort study.docx by Cong Liu (66219)

“…In contrast, short or intermediate sleep duration accompanied by decrease in BMI was associated with a reduced risk of DKD, with HRs of 0.50 (95% CI: 0.31-0.82) and 0.61 (95% CI:0.47-0.80), respectively.…”

Supplementary Material for: Antiproteinuric Effect of Chemokine C-C Motif Ligand 2 Inhibition in Subjects with Acute Proliferative Lupus Nephritis by Ble A. (4128712)

“…<i>Results:</i> Urinary CCL2 significantly decreased during bindarit therapy (p = 0.008 vs. baseline) with a reduction that approximated 50% at study end. …”

Table1_Age and gender influence on clinical manifestations of thyroid-associated ophthalmopathy: a case series of 2479 Chinese patients.xlsx by Mei Yang (51996)

“…As age increased, there was a decline in the percentage of females (γ=-0.168, p<0.001). …”

Supplementary Material for: Efficacy of Omalizumab in Mastocytosis: Allusive Indication Obtained from a Prospective, Double-Blind, Multicenter Study (XOLMA Study) by Distler M. (8332950)

“…After 6 months the median AFIRMM score decreased 50% from 52.0 to 26.0 in the omalizumab group versus 104.0–102.0 in the placebo group (<i>p</i> = 0.286); however, the difference was not significant (<i>p</i> = 0.941). …”

Image_1_Deficiency of C-reactive protein or human C-reactive protein transgenic treatment aggravates influenza A infection in mice.jpeg by Zhuohan Zhang (6400985)

“…However, it is unclear on the pathogenesis associated with CRP in influenza infections. Here, we used influenza A H1N1 CA04 to infect human CRP transgenic mice (KI), CRP knockout mice (KO), and wild-type mice (WT), respectively, and compared the viral pathogenicity and associated immune response in those mice. …”

TAC-induced CaMKIIδB activation and CaMKII-HDAC4 complex translocalization are blocked by a calmodulin antagonist. by Ying-Mei Lu (206101)

“…<p>(<b>A</b>) Representative hearts (upper) and H&E staining of heart tissues (lower) in mice treated with either a TAC or TAC+ calmodulin antagonist (DY-9836, 20 mg/kg for six weeks). …”

Image_1_A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice.tif by Qinjun Chu (4051534)

“…</p><p>Methods: Dexmedetomidine 0.25, 0.5, and 1 mg/kg accompanied with Esk 50 mg/kg were administrated on Kunming mice to assess the anesthesia quality for 1 h. …”

<i>Pax2.1</i> and <i>pax6a</i> expression is altered in <i>sox11</i> morphants. by Lakshmi Pillai-Kastoori (596161)

“…<p>(A) Fluorescent in situ hybridization on transverse sections from control and <i>sox11</i> morphants with probes for <i>pax2.1</i> and <i>pax6a</i>. …”

Data Sheet 1_Global burden of nasopharyngeal carcinoma attributable to alcohol use: a 1990–2021 analysis with projections to 2040.pdf by Zhenyi Lu (22004786)

Data Sheet 2_Global burden of nasopharyngeal carcinoma attributable to alcohol use: a 1990–2021 analysis with projections to 2040.zip by Zhenyi Lu (22004786)